Literature DB >> 20202840

Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold.

Lun K Tsou1, Ginger E Dutschman, Elizabeth A Gullen, Maria Telpoukhovskaia, Yung-Chi Cheng, Andrew D Hamilton.   

Abstract

A potential anti-HIV and HCV drug candidate is highly desirable as coinfection has become a worldwide public health challenge. A potent compound based on a tetrabutoxy-calix[4]arene scaffold that possesses dual inhibition for both HIV and HCV is described. Structural activity relationship studies demonstrate the effects of lower-rim alkylation in maintaining cone conformation and upper-rim interacting head groups on the calix[4]arene play key roles for its potent dual antiviral activities. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202840      PMCID: PMC2849157          DOI: 10.1016/j.bmcl.2010.02.043

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy.

Authors:  G Ascherl; C Hohenadl; O Schatz; E Shumay; J Bogner; L Eckhart; E Tschachler; P Monini; B Ensoli; M Stürzl
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

2.  Elevated liver enzymes following initiation of antiretroviral therapy.

Authors:  M Velasco; C Guijarro
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

3.  Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.

Authors:  Huchen Zhou; De-an Wang; Laura Baldini; Eileen Ennis; Rishi Jain; Adam Carie; Saïd M Sebti; Andrew D Hamilton
Journal:  Org Biomol Chem       Date:  2006-05-10       Impact factor: 3.876

Review 4.  Biochemistry of the para-sulfonato-calix[n]arenes.

Authors:  Florent Perret; Adina N Lazar; Anthony W Coleman
Journal:  Chem Commun (Camb)       Date:  2006-03-10       Impact factor: 6.222

5.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

6.  Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity.

Authors:  K D Chi; R A McPhee; A S Wagner; J J Dietz; P Pantazis; A S Goustin
Journal:  Oncogene       Date:  1997-08-28       Impact factor: 9.867

7.  Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.

Authors:  M A Blaskovich; Q Lin; F L Delarue; J Sun; H S Park; D Coppola; A D Hamilton; S M Sebti
Journal:  Nat Biotechnol       Date:  2000-10       Impact factor: 54.908

Review 8.  Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.

Authors:  Ashwani-K Singal; Bhupinderjit S Anand
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

9.  Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Authors:  Jiazhi Sun; Michelle A Blaskovich; Rishi K Jain; Frederic Delarue; Daniel Paris; Steven Brem; Marguerite Wotoczek-Obadia; Qing Lin; Domenico Coppola; Kihang Choi; Michael Mullan; Andrew D Hamilton; Saïd M Sebti
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

Review 10.  Coinfection with HIV-1 and HCV--a one-two punch.

Authors:  Arthur Y Kim; Raymond T Chung
Journal:  Gastroenterology       Date:  2009-06-21       Impact factor: 22.682

View more
  7 in total

1.  Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library.

Authors:  Landon R Whitby; Kristopher E Boyle; Lifeng Cai; Xiaoqian Yu; Miriam Gochin; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2012-03-03       Impact factor: 2.823

Review 2.  Calix[4]API-s: fully functionalized calix[4]arene-based facial active pharmaceutical ingredients.

Authors:  Fazel Nasuhi Pur
Journal:  Mol Divers       Date:  2020-01-31       Impact factor: 2.943

3.  Blocking HIV-1 entry by a gp120 surface binding inhibitor.

Authors:  Lun K Tsou; Chin-Ho Chen; Ginger E Dutschman; Yung-Chi Cheng; Andrew D Hamilton
Journal:  Bioorg Med Chem Lett       Date:  2012-03-02       Impact factor: 2.823

4.  A Calixarene Assembly Strategy of Combined Anti-Neuroinflammation and Drug Delivery Functions for Traumatic Brain Injury Therapy.

Authors:  Chunxiao Wang; Yu-Xuan Chang; Xi Chen; Lihuan Bai; Heping Wang; Yu-Chen Pan; Chunqiu Zhang; Dong-Sheng Guo; Xue Xue
Journal:  Molecules       Date:  2022-05-06       Impact factor: 4.927

Review 5.  Therapeutic development in targeting protein-protein interactions with synthetic topological mimetics.

Authors:  Lun K Tsou; Yao Cheng; Yung-Chi Cheng
Journal:  Curr Opin Pharmacol       Date:  2012-05-10       Impact factor: 5.547

6.  Inclusion Complexes of a New Family of Non-Ionic Amphiphilic Dendrocalix[4]arene and Poorly Water-Soluble Drugs Naproxen and Ibuprofen.

Authors:  Khalid Khan; Syed Lal Badshah; Nasir Ahmad; Haroon Ur Rashid; Yahia Mabkhot
Journal:  Molecules       Date:  2017-05-11       Impact factor: 4.411

7.  Calixtyrosol: a Novel Calixarene Based Potent Radical Scavenger.

Authors:  Fazel Nasuhi Pur; Karim Akbari Dilmaghani
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.